Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative allogeneic hematopoietic cell transplantation with peri-transplant rituximab for advanced chronic lymphocytic leukemia
2009-017449-72Phase 2Active
- Sponsor
- FRED HUTCHINSON CANCER RESEARCH CENTER UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE SEATTLE CHILDREN
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and prolymphocytic leukemia (PLL), sponsored by FRED HUTCHINSON CANCER RESEARCH CENTER UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE SEATTLE CHILDREN. Primary endpoint: Overall survival at 18 months. Started Dec 2009; status: active.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on 2009-017449-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017449-72.